Revive Therapeutics Ltd Stock Price, News & Analysis

Revive Therapeutics (OTCQB: RVVTF) has been approached by a prominent U.S. University Cancer Institute researcher to investigate Bucillamine's potential in cancer treatment, specifically for enhancing anti-tumor effects in advanced solid tumors. The research would be supported by NIH and other government funding.

The investigation builds on existing partnerships, including one with Defence R&D Canada – Suffield Research Centre, which is evaluating Bucillamine for nerve agent exposure treatment. The cancer research focuses on Bucillamine's role as a thiol donor that could neutralize reactive oxygen species and replenish reduced glutathione in the tumor microenvironment (TME), potentially amplifying antitumor effects.

This approach aims to address challenges in nucleic acid-based therapies, particularly regarding drug delivery and stability in the TME, which is characterized by low oxygen levels and elevated reduced glutathione.

Revive Therapeutics (RVVTF) has acquired DiagnaMed's molecular hydrogen intellectual property through an asset purchase agreement dated March 31, 2025. The acquisition, valued at $50,000, will be satisfied through the issuance of one million common shares at $0.05 per share.

The acquired assets include a provisional patent application for pharmaceutical-based methods using molecular hydrogen to treat neurological and mental health disorders, including Dementia, Parkinson's disease, Traumatic brain injury, Depression, Anxiety, and Post-traumatic stress disorder. Additionally, the acquisition includes research activities and an FDA Orphan Drug Designation (ODD) for molecular hydrogen in treating ALS.

ALS affects approximately 50,000 people in the U.S. and Europe, with over 5,000 new cases diagnosed annually. The disease has a life expectancy of two to six years after diagnosis, with no known cure currently available.

Revive Therapeutics (OTCQB: RVVTF) held its annual shareholder meeting on March 18, 2025, where several key decisions were made. Shareholders elected five board members, including CEO Michael Frank and four independent directors: Joshua Herman, Andrew Lindzon, William Jackson, and Christian Scovenna.

The meeting also resulted in the approval of Horizon Assurance LLP as the company's auditor, authorization for directors to set auditor remuneration, and continuation of the company's 10% rolling incentive stock option plan. Notably, following shareholder feedback, the Board decided not to proceed with a proposed amendment to consolidate outstanding Common Shares.

Revive Therapeutics (RVVTF) has entered into a non-binding letter of intent to acquire DiagnaMed Holdings Corp.'s intellectual property related to molecular hydrogen treatments for neurological and mental health disorders. The acquisition includes:

• A provisional patent application for pharmaceutical-based methods and compositions for molecular hydrogen treatments
• Research work and FDA Orphan Drug Designation for molecular hydrogen in treating ALS

The acquisition is expected to close by March 31, 2025. The company aims to develop treatments for conditions including Dementia, Parkinson's, Traumatic brain injury, Depression, Anxiety, and PTSD. Additionally, Revive secured a $65,000 loan at 8% interest, maturing February 19, 2026, for working capital needs.

Revive Therapeutics (OTCQB: RVVTF) has provided an update on its R&D focus for Bucillamine, an oral thiol-based drug with anti-inflammatory and antiviral properties. The company is pursuing two main programs:

1. Medical Countermeasures: In partnership with Defence R&D Canada, evaluating Bucillamine as a treatment for nerve agent exposure. The research study is expected to complete in February 2025.

2. Infectious Diseases: Targeting Long COVID as initial indication. Previous Phase 3 trial data showed Bucillamine demonstrated 29.1% improvement over placebo in time to normal oxygen saturation for patients with oxygen saturation <96% at baseline. The company plans to submit a Phase 2 study protocol to FDA by Q1-2025, with expected approval in Q2-2025.

Additionally, the company disclosed a consent judgment regarding an arbitration award of €301,806.5 and USD$160,800 plus costs, with enforcement delayed until May 22, 2025.

Revive Therapeutics (OTCQB: RVVTF) provided an update on their research study evaluating Bucillamine as a potential treatment for nerve agent exposure, conducted in partnership with Defence R&D Canada – Suffield Research Centre (DRDC). The first set of animal trials, including soman controls and bucillamine pretreated subjects, has been completed, with DRDC now analyzing GABA receptor downregulation data.

If the results prove significant, Revive and DRDC will discuss future development paths. Promising outcomes could lead to further studies for FDA and Health Canada approvals for Bucillamine's use in treating nerve agent or organophosphate pesticide poisoning, as well as exploring its potential for traumatic brain injury from concussive forces and viral infections.

Bucillamine, being a more effective antioxidant than n-acetylcysteine (NAC), could potentially provide increased efficacy against seizure activity while reducing anticoagulant and bleeding event risks associated with NAC. The research focuses on neuroprotection of GABA(A) receptors, important for current anticonvulsant therapies.

Revive Therapeutics (OTCQB: RVVTF) announced the publication of research demonstrating psilocybin's potential as a novel therapeutic approach for stroke treatment. The study, published in BMC Neuroscience, showed that psilocybin reduced brain infarction and improved locomotor behavior in stroke rats by regulating BDNF expression. The research supports the company's PCT application for using psilocybin to treat neurological brain injury and migraines, acquired from PharmaTher Holdings in February 2021. The company is developing novel delivery methods, including an oral thin-film and microneedle patch for psilocybin administration.

Revive Therapeutics (OTCQB: RVVTF) announced an update on their research study evaluating Bucillamine as a potential treatment for nerve agent exposure, conducted in partnership with Defence R&D Canada – Suffield Research Centre. The study is progressing with final results expected by end of 2024. If promising, results will determine further studies for FDA and Health Canada approvals for nerve agent and organophosphate pesticide poisoning treatments. Bucillamine, being a more effective antioxidant than n-acetylcysteine (NAC), could potentially provide increased efficacy against seizure activity while reducing anticoagulant and bleeding risks associated with NAC.

Revive Therapeutics (OTCQB: RVVTF) has announced a strategic focus on advancing the clinical development of Bucillamine, an oral thiol-based drug with anti-inflammatory and antiviral properties. The company is concentrating on three main programs:

1. Nerve Agent Exposure: In partnership with Defence R&D Canada, evaluating Bucillamine as a potential treatment for nerve agent exposure, with research expected to complete in October 2024.

2. Emerging Infections: Exploring Bucillamine's potential use in various viral infections, including monkeypox (Mpox).

3. Long COVID: Finalizing a Phase 2 study protocol for FDA submission by end of 2024, with expected approval in Q1-2025.

Revive has decided not to pursue the development of a Long COVID diagnostic product. The company emphasizes that no claims are being made about Bucillamine's ability to treat or cure these conditions at this time.